Group 1 - The core announcement is that Li Jianwei has resigned from multiple positions at Xintai Medical, effective December 30, 2025 [1] - Positions Li Jianwei is resigning from include: (i) Co-Company Secretary; (ii) Agent for receiving legal documents and notices in Hong Kong; and (iii) Authorized representative under the Companies Ordinance and Listing Rules [1] - Following Li's resignation, Yang Lishan has been appointed to the aforementioned positions, effective December 30, 2025 [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 LEPU SCIENTECH MEDICAL TECHNOLOGY (SHANGHAI) CO., LTD.* 樂普心泰醫療科技（上海）股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2291） 1 (i) 聯席公司秘書（「聯席公司秘書」）； (ii) 根據香港聯合交易所有限公司（「聯交所」）證券上市規則（「《上市規則》」）第 19A.13(2)條的規定，代表本公司在香港送達法律程序文件及通知書的代理人 （「法律程序文件接收代理人」）；及 (iii) 《公司條例》（香港法例第622章）第16部及《上市規則》第3.05條規定的授權代 表（「授權代表」）。 聯席公司秘書、法律程序文件接收代理人及授權代表變更 聯席公司秘書、法律程序文件接收代理人及授權代表變更 樂普心泰醫療科技（上海）股份有限公司（「本公司」）及其附屬公司（統稱「本集 團」）的董事（「董事」）會（「董事會」）宣佈，李健威 ...

Core Viewpoint - The Shenzhen-Hong Kong Stock Connect Medical Index (港币) closed at 4287.1 points, down 0.23%, with a trading volume of 7.011 billion yuan and a turnover rate of 0.72% [1] Group 1: Index Performance - On the day, 18 constituent stocks rose, with Blue Sail Medical leading with a 10.0% increase, while 36 stocks declined, with Yimai Sunshine leading the decline at 3.83% [1] - The net outflow of main funds from the Shenzhen-Hong Kong Stock Connect Medical Index constituents totaled 115 million yuan, while retail investors saw a net inflow of 181 million yuan [1] Group 2: Constituent Stocks Details - The top ten constituent stocks of the Shenzhen-Hong Kong Stock Connect Medical Index include: - Yimai Sunshine (hk02522) with a market cap of 3.43 billion yuan and a price drop of 3.83% [1] - Weikang Medical (hk00853) with a market cap of 17.4 billion yuan and a price drop of 3.38% [1] - Weikang Robotics (hk02252) with a market cap of 19.21 billion yuan and a price drop of 2.84% [1] - Wu Hai Biotechnology (hk06826) with a market cap of 5.46 billion yuan and a price drop of 2.27% [1] - Dian Diagnostics (sz300244) with a market cap of 9.19 billion yuan and a price drop of 2.13% [1] - Ruimaite (sz301367) with a market cap of 7.59 billion yuan and a price drop of 2.08% [1] - Tuya Holdings (hk01099) with a market cap of 56.54 billion yuan and a price drop of 1.96% [1] - Yidu Technology (hk02158) with a market cap of 4.83 billion yuan and a price drop of 1.96% [1] - Xintai Medical (hk02291) with a market cap of 5.23 billion yuan and a price drop of 1.83% [1] - Chunli Medical (hk01858) with a market cap of 5.26 billion yuan and a price drop of 1.76% [1]

Core Viewpoint - The stock price of XinTai Medical (02291) has been on a downward trend since August 26, following a significant share reduction by its major shareholder, Lepu Medical, which has led to decreased investor confidence and trading volume [1][2][4]. Group 1: Stock Performance - On November 19, XinTai Medical's stock price hit a low of HKD 17.95, marking the first time it fell below HKD 18 since a 49.26% increase on April 22 [1]. - The stock closed at HKD 17.20 on December 8, nearing its recent low of HKD 17.01 [1]. - The downward trend began after the major shareholder's announcement on August 26, which caused an immediate sell-off, leading to a 12.75% drop on that day [3]. Group 2: Shareholder Actions - On August 26, Lepu Medical announced the sale of 11.14 million shares at HKD 22.79 each, representing 3.21% of XinTai Medical's total issued shares [2]. - Despite the announcement claiming confidence in the company's operations, the immediate market reaction was negative, with significant sell-offs and a subsequent decline in trading volume [4]. Group 3: Market Dynamics - Following the announcement, trading volume dropped significantly, with daily averages falling below 1 million shares, indicating a lack of confidence among investors [4]. - The stock's performance has raised concerns about XinTai Medical's status in the Hong Kong Stock Connect, with an average market capitalization of HKD 68.85 billion, just above the HKD 60.71 billion threshold [6]. Group 4: Industry Context - A nationwide procurement initiative for structural heart disease occluders has been initiated, which could impact pricing and market dynamics for XinTai Medical's products [9][10]. - The market for heart occluders is projected to exceed HKD 60 billion by 2025, with significant growth expected [10]. - XinTai Medical's revenue from congenital heart disease occluders was HKD 161 million in the first half of the year, accounting for 48.7% of total revenue, indicating its importance to the company's financial health [11].

Core Viewpoint - The stock price of XinTai Medical (02291) has been on a downward trend since August 26, following a major shareholder's announcement of share reduction, leading to concerns about the company's market position and potential risks to its inclusion in the Hong Kong Stock Connect program [1][5]. Group 1: Stock Performance - On November 19, XinTai Medical's stock price hit a low of HKD 17.95, marking the first time it fell below HKD 18 since a significant increase of 49.26% on April 22 [1]. - The stock closed at HKD 17.20 on December 8, nearing its recent low of HKD 17.01, indicating a continued decline [1]. - The downward trend began after the major shareholder, Lepu Medical, announced the sale of 11.14 million shares at HKD 22.79 each, representing approximately 3.21% of the company's total issued shares [1][2]. Group 2: Market Reaction - Following the announcement of the share reduction, there was immediate selling pressure, with the stock price dropping nearly 9% within the first minute of trading on August 26, and closing down 12.75% for the day [2]. - The stock has since experienced a prolonged decline, characterized by a "seven consecutive days of decline" followed by an "eleven consecutive days of decline," indicating a lack of buying support [2][3]. Group 3: Trading Volume and Market Sentiment - The trading volume on the day of the announcement reached 16.16 million shares, but subsequent days saw average daily volumes drop below 1 million shares, reflecting a lack of confidence among investors [3]. - The low trading volume and continuous decline suggest that investors are hesitant about the stock's value growth, leading to a cautious market sentiment [3]. Group 4: Potential Risks to Market Position - XinTai Medical's average market capitalization during the review period is HKD 6.885 billion, only slightly above the HKD 6.071 billion threshold for inclusion in the Hong Kong Stock Connect program [5]. - The next review for the Hong Kong Stock Connect is scheduled for March 2025, with results announced on February 25, 2025, creating a critical timeframe for the company to stabilize its market position [5]. Group 5: Industry Developments - Recent announcements regarding the nationwide centralized procurement of structural heart disease occluders could significantly impact XinTai Medical's market dynamics, as this initiative aims to lower prices and increase competition [10][11]. - The market for heart occluders is projected to exceed HKD 6 billion by 2025, with a double-digit growth rate, indicating a robust demand for these medical devices [10]. - XinTai Medical's revenue from congenital heart disease occluders was HKD 161 million in the first half of the year, accounting for 48.7% of total revenue, highlighting its importance as a core revenue source [11].

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年11月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 樂普心泰醫療科技（上海）股份有限公司 (「本公司」) 呈交日期: 2025年12月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02291 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 346,749,997 | RMB | | 1 RMB | | 346,749,997 | | 增加 / 減少 (-) | | | | | | RMB | | | | 本月底結存 | | | 346,749,997 | RMB | | 1 RMB | | 346,749,997 | 本月底法定/註冊股本總額： ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年10月31日 狀態: 新提交 FF301 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02291 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 346,749,997 | RMB | | 1 RMB | | 346,749,997 | | 增加 / 減少 (-) | | | | | | RMB | | | | 本月底結存 | | | 346,749,997 | RMB | | 1 RMB | | 346,749,997 | 本月底法定/註冊股本總額： RMB 346,749,997 備註： 因本公司是於中華人民共和國註冊成立，「法定股本」之概念不適用於本公司。於I節中所示的資料是指本公司的「註冊股本」。 ...

Group 1: Heart Disease Medical Devices - Haitong International maintains an "outperform" rating for Xintai Medical, with a target price of HKD 28.94, highlighting its leadership in congenital heart disease intervention devices and a projected revenue growth of 32.4% year-on-year for H1 2025 [1] Group 2: Express Delivery Services - CITIC Securities maintains a "buy" rating for Jitu Express, noting a 23.1% year-on-year increase in parcel volume in Q3, with Southeast Asia's growth rate reaching 78.7%, driven by cost and efficiency advantages [2] - Shenwan Hongyuan also maintains an "accumulate" rating for Jitu Express, reporting a market share increase to 32.8% and a recovery in domestic express delivery prices, despite a downward revision in profit forecasts [3] Group 3: Healthcare and Medical Services - CITIC Jiantou maintains a "buy" rating for China Resources Medical, indicating that while H1 2025 performance may be pressured by declining average medical insurance fees, the company holds a solid regional leadership position [4] - CITIC Jiantou also maintains a "buy" rating for Weitai Medical, projecting a 63.1% year-on-year revenue growth for H1 2025, with significant narrowing of losses and potential for breakeven by year-end [5] Group 4: Consumer Goods and Retail - Guosen Securities maintains an "outperform" rating for Shangmei Co., with a target price of HKD 120.9, emphasizing strong growth in net profit at a compound annual growth rate of 130% from 2022 to 2024 [6] - Huaxin Securities maintains an "accumulate" rating for Nayuki Tea, benefiting from demand catalyzed by Meituan's delivery subsidies and seasonal effects, with improved profitability through product innovation [7] - Huaxin Securities also maintains a "buy" rating for Wugu Mofang, reporting a 14% revenue growth and an 18% net profit increase for H1 2025, driven by strong performance in offline channels [8] Group 5: Food and Beverage - Guangda Securities maintains an "accumulate" rating for Xiaocaiyuan, noting its position as a leading casual dining chain with a customer price range of HKD 50-70, and plans to expand to 1,000 stores by the end of 2026 [10] - Xibu Securities initiates coverage on China Resources Beverages with an "accumulate" rating and a target price of HKD 15, highlighting a market share of 32.7% and improvements in gross margin through increased self-production [11]

Core Viewpoint - The company is a leader in congenital heart disease interventional medical devices in China, with steady profit growth from its biodegradable technology and a new growth curve from heart valve products, which are expected to significantly enhance profits over the next 1-5 years [1][2]. Investment Highlights - The company is rated "Outperform" with a target price of 26.62 CNY / 28.94 HKD based on a cautious approach using both PE and PB valuation methods, predicting EPS for 2025-2027 to be 0.89, 1.15, and 1.45 CNY respectively [1]. - For the first half of 2025, the company achieved revenue of 330 million CNY, a year-on-year increase of 32.4%, and a net profit attributable to shareholders of 182 million CNY, up 29.8% year-on-year [1]. Industry Insights - The concept of "interventional without implantation" is gaining traction, with biodegradable occluders being highly favored, as they reduce long-term complications and offer significant clinical advantages over metal occluders [2]. - The heart valve treatment market in China is entering a harvest phase, with a projected CAGR of 69.8% from 2021 to 2025, indicating substantial market potential [2]. - The company's ScienCrown transcatheter aortic valve system, as the world's first self-expanding short valve with balloon expansion advantages, achieved over 40 million CNY in sales within six months, suggesting strong growth potential as commercialization progresses [2].

Group 1 - The core viewpoint of the report is that Xintai Medical (02291) is rated "outperform" with a target price of 26.62 CNY / 28.94 HKD, based on its comprehensive product layout and strong development in new business segments [1] - The company achieved a revenue of 330 million CNY in H1 2025, representing a year-on-year growth of 32.4%, and a net profit attributable to shareholders of 182 million CNY, with a year-on-year increase of 29.8% [1] - Xintai Medical is a leader in congenital heart disease interventional medical devices in China, with traditional business benefiting from biodegradable technology and the introduction of heart valve products as a second growth curve [1] Group 2 - The penetration rate of cardiac valve interventional surgeries in China is low, indicating significant market potential, with a projected CAGR of 69.8% from 2021 to 2025 [2] - The ScienCrown transcatheter aortic valve system, as the world's first self-expanding short valve with balloon expansion advantages, achieved over 40 million CNY in sales within six months [2] - The sales growth of this product is expected to accelerate as the commercialization process deepens [2]